Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PI3Kβ or p110β) is the catalytic subunit of class IA phosphoinositide 3-kinases (PI3Ks). These enzymes regulate cell growth, proliferation, differentiation, survival, and metabolism by phosphorylating phosphatidylinositols, generating PIP₃. PI3Kβ plays a critical role in the PI3K/AKT pathway and has unique nuclear functions, including DNA replication control, distinguishing it from other class I isoforms. Dysregulation of PI3Kβ is implicated in oncogenesis, making it a target for cancer therapy. PTEN antagonizes PI3Kβ activity. Several inhibitors targeting different isoforms have been developed for cancer therapy; some drugs such as copanlisib target multiple class I isoforms including β.
Inhibition of phosphatidylinositol 3-kinase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PI3Kβ).